# Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

> **NCT06449482** · PHASE1,PHASE2 · TERMINATED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia, Adult

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT06449482
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-05
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The number of participants in the study did not meet expectations
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06449482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06449482, "Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06449482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*